Third Rock Leads $30 Mil. Series B For CytomX
This article was originally published in The Pink Sheet Daily
Executive Summary
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
You may also be interested in...
Bristol Signs Two Cancer Immunotherapy Partners With Eye On Combos
Bristol will pay $50 million upfront to use CytomX’s Probody platform for up to four cancer immunotherapy targets. The company also partnered with InCyte to study its PD-1 inhibitor nivolumab with Incyte’s oral indoleamine dioxygenase-1 inhibitor.
CytomX’s Approach To Antibody-Drug Conjugates Earns Deal With Pfizer
The privately held California biotech calls its ADC technology Probody Drug Conjugates and claims it can create antibodies that will activate in a tumor’s micro-environment, while remaining dormant in healthy tissue. Pfizer is paying $25 million divided between upfront cash and preclinical milestones for a licensing deal around CytomX’s Probody Platform technology.
Big Pharma's Appetite for Biologics Platforms Fuels New Company Creation
With the industry on the cusp of a "me-better" era in biotherapies, Big Pharma has more incentive than ever to invest in novel platforms that can build better biologics. Start-Up profiles ArGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology